Table 6: Risk of arterial/venous thromboembolism with AI's and recommendations.
|Drug name||Risk of ATE||Risk of VTE||Recommendations|
|Axitinib||✓||✓||Axitinib should be used with caution in patients who are at increased
risk of thromboembolic events as well as in patients who have a prior
history of these events .
Bevacizumab should be discontinued in all patients who experience a
Permanently discontinue Bevacizumab therapy in patients with life-threatening
|Cabozantinib||✓||✓||Should be discontinued in patients who experience acute MI as well as
in patients who develop any other clinically significant arterial
thrombotic complications .
|Erlotinib||✓||✓||No specific recommendations .|
Patients who are being started on Nilotinib should be advised to seek
Before starting Nilotinib, patients cardiovascular status should be
|Panitumumab||Not reported||✓||No specific recommendations .|
|Pazopanib||✓||✓||Pazopanib should be used with caution in patients with a history of
ATE`s or who are at increased risk of ATE`s. All patients should be
monitored for signs and symptoms VTE and PE during Pazopanib
|Ponatinib||✓||✓||In patients suspected of developing ATE`s, it is recommended that the
treatment should be discontinued and a benefit-risk re-consideration
should guide the decision to restart the therapy with Ponatinib. In
patients who develop serious VTE, dose modification or discontinuation
of the drug should be considered .
|Ramucirumab||✓||Not reported||It should be permanently discontinued in patients experiencing a severe
|Regorafenib||✓||Not reported||It should be discontinued in patients who develop new or acute onset
myocardial ischemia or infarction. Resumption of the treatment should
be based upon consideration of potential benefits versus risks of further
cardiac ischemia .
|Sorafenib||✓||Not reported||Temporary or permanent discontinuation of sorafenib should be
considered in case of development of cardiac ischemia or infarction in a
|Vandetanib||✓||Not reported||Vandetanib should be discontinued in patients who experience severe
thrombotic events .
|Ziv-Aflibercept||✓||Not reported||Ziv-aflibercept should be discontinued in patients experiencing an ATE